Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

225 Ac PSMA R2 - Novartis Pharmaceuticals

Next Previous
X
Search
Drug Profile

225 Ac PSMA R2 - Novartis Pharmaceuticals

Alternative Names: 225Ac-PSMA-R2; [225Ac]Ac-PSMA-R2; AAA-802; AAA-802 - Novartis

Latest Information Update: 27 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis Pharmaceuticals
  • Class Antineoplastics; Drug conjugates; Radioisotopes; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Prostate cancer

Most Recent Events

  • 07 Nov 2023 Phase-I/II clinical trials in Prostate cancer (Second-line therapy or greater, Refractory metastatic disease) in France (unspecified route) (NCT05983198)
  • 18 Aug 2023 Preclinical trials in Prostate cancer in USA (unspecified route)
  • 09 Aug 2023 Novartis Pharmaceuticals plans phase-I/II trial for Prostate cancer (Refractory metastatic disease, Second-line therapy or greater)in September 2023 (NCT05983198),

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top